Breadcrumb Navigation

Melanom: A Multicenter Phase 2, Open Label Study of Intratumoral Tavokinogene Telseplasmid (Tavo, pIL-12) Plus Electroporation in Combination With Intravenous Pembrolizumab in Patients With Stage III/IV Melanoma Who Are Progressing on Either Pembrolizumab or Nivolumab Treatment (Keynote 695)

Stadium/Indikation inkl. Kurzinfo

Melanom – 2nd line

Stadium II/IV nach Progress unter Immuntherapie mit antiPD1
(Mit kutanen/subkutanen Metastasen)

Anti-PD1 + intraläsionales IL-12 Plasmid

Kurztitel

OncoSec OMS-I103
MK3475-695 (PISCES)
NCT03132675

Offizieller Titel

A Multicenter Phase 2, Open Label Study of Intratumoral Tavokinogene Telseplasmid (Tavo, pIL-12) Plus Electroporation in Combination With Intravenous Pembrolizumab in Patients With Stage III/IV Melanoma Who Are Progressing on Either Pembrolizumab or Nivolumab Treatment (Keynote 695)

PI (Principal Investigator)

Prof. Reinhard Dummer

Zuständige Ärztin

Fabienne Fröhlich

Tel. +41 43 253 25 13

Zuständige Ärztin

Corinne Eggenschwiler

Tel. +41 43 253 03 96

Behandelnder Fachbereich

Dermatologische Klinik